BIP Winter 2025

respond well to that drug,” Chaihorsky explains. “That’s a problem brokers can help solve by incorporating proven the same and hoped for the best. Precision medicine lets us treat people based on their specific biology. — Lena Chaihorsky, ALVA10 “ ” Historically, we’ve treated everyone

Chaihorsky has spent her career focused on how data from DNA, RNA and other biomarkers can help predict disease risk, guide drug selection and improve patient outcomes. “Historically, we’ve treated everyone the same and hoped for the best,” she says. “Precision medicine lets us treat people based on their specific biology, leading to more effective and efficient care.” Her path to NABIP began with a realization: While commercial insurers often struggle to capture the full value of precision medicine, employers — and the brokers who serve them — stand to benefit the most. “If an employer is paying for 100 prescriptions of Humira, only about 40 people will actually

precision medicine tools into their clients’ benefit strategies.” The task force will focus on how to make these technologies easy for brokers to understand, source and deliver. “We’re bringing the science,” says Chaihorsky. “We need brokers’ expertise to figure out how to package and present it in ways that employers can immediately act on.” By aligning healthcare innovation with benefit design, NABIP’s Precision Medicine Task Force aims to help brokers unlock new value for employers and improve access to more personalized care for employees. Recruitment is expected to wrap up by early winter, with the group’s first recommendations anticipated in 2026.

TopVector / iStock

Keep an eye on NABIP’s weekly newsletters and nabip.org for upcoming information on the Precision Medicine Task Force.

Winter 2025 bip magazine 9